Nutrien (NTR) reported $5.35 billion in income for the quarter ended September 2024, representing a year-over-year decline of 5%. EPS of $0.39 for a similar interval compares to $0.35 a 12 months in the past.
The reported income compares to the Zacks Consensus Estimate of $5.36 billion, representing a shock of -0.28%. The corporate delivered an EPS shock of -11.36%, with the consensus EPS estimate being $0.44.
Whereas traders intently watch year-over-year adjustments in headline numbers — income and earnings — and the way they examine to Wall Road expectations to find out their subsequent plan of action, some key metrics at all times present a greater perception into an organization’s underlying efficiency.
Since these metrics play a vital position in driving the top- and bottom-line numbers, evaluating them with the year-ago numbers and what analysts estimated about them helps traders higher undertaking a inventory’s worth efficiency.
Right here is how Nutrien carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Tonnes Offered – Potash – Complete: 4,152 KTon versus 3,572.55 KTon estimated by 4 analysts on common.
- Tonnes Offered – Nitrogen: 2,455 KTon versus the four-analyst common estimate of two,604.97 KTon.
- Crop Vitamins Gross sales Volumes in tonnes – Complete: 1,887 KTon in comparison with the two,229.59 KTon common estimate primarily based on 4 analysts.
- Crop Vitamins Gross sales Volumes in tonnes – Worldwide: 956 KTon versus 902.06 KTon estimated by 4 analysts on common.
- Gross sales- Retail Complete: $3.27 billion versus $3.29 billion estimated by 5 analysts on common. In comparison with the year-ago quarter, this quantity represents a -6.3% change.
- Gross sales- Potash: $1.03 billion in comparison with the $941.40 million common estimate primarily based on 5 analysts. The reported quantity represents a change of -7.4% 12 months over 12 months.
- Gross sales- Phosphate: $467 million versus the five-analyst common estimate of $483.44 million. The reported quantity represents a year-over-year change of -9.5%.
- Gross sales- Nitrogen: $916 million in comparison with the $926.40 million common estimate primarily based on 5 analysts. The reported quantity represents a change of +10.6% 12 months over 12 months.
- Gross sales- Retail (Nutrient Ag Options)- Crop safety merchandise: $1.52 billion versus the four-analyst common estimate of $1.47 billion. The reported quantity represents a year-over-year change of -3.1%.
- Gross sales- Retail (Nutrient Ag Options)- Crop vitamins: $1.09 billion in comparison with the $1.15 billion common estimate primarily based on 4 analysts. The reported quantity represents a change of -12.6% 12 months over 12 months.
- Internet Gross sales- Eliminations: -$275 million versus the four-analyst common estimate of -$313.99 million. The reported quantity represents a year-over-year change of +5.4%.
- Internet Gross sales- Phosphate: $412 million versus $423.29 million estimated by 4 analysts on common. In comparison with the year-ago quarter, this quantity represents a -7.2% change.
View all Key Company Metrics for Nutrien here>>>
Shares of Nutrien have returned +4.2% over the previous month versus the Zacks S&P 500 composite’s +0.7% change. The inventory at present has a Zacks Rank #3 (Maintain), indicating that it may carry out consistent with the broader market within the close to time period.
Zacks Names #1 Semiconductor Inventory
It is just one/9,000th the dimensions of NVIDIA which skyrocketed greater than +800% since we advisable it. NVIDIA remains to be sturdy, however our new prime chip inventory has way more room to increase.
With sturdy earnings development and an increasing buyer base, it is positioned to feed the rampant demand for Synthetic Intelligence, Machine Studying, and Web of Issues. International semiconductor manufacturing is projected to blow up from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Nutrien Ltd. (NTR) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
